Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD
29 nov. 2022 16h05 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on rare endocrine disorders, announced that the Company will...
Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference
22 nov. 2022 16h05 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials...
Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates
14 nov. 2022 06h10 HE
|
Lumos Pharma, Inc.
-- Interim Data for Potentially the First Oral Medication for PGHD from Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials Met Expectations with an Encouraging Growth Response of 8.6 cm/yr at six...
Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
14 nov. 2022 06h00 HE
|
Lumos Pharma, Inc.
- LUM-201, potentially the first oral medication for PGHD, met expectations in an interim analysis of two Phase 2 trials evaluating growth in Pediatric Growth Hormone Deficiency (PGHD) - - Interim...
Lumos Pharma to Participate in the Cantor Neurology & Psychiatry Conference
26 sept. 2022 16h05 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials...
Lumos Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
31 août 2022 09h00 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials...
Lumos Pharma Announces Share Repurchase Program
16 août 2022 07h30 HE
|
Lumos Pharma, Inc.
-- Plan to Repurchase Up to $3 Million of Common Shares -- AUSTIN, Texas, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (“The Company,” NASDAQ:LUMO), a biopharmaceutical company advancing...
Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates
09 août 2022 16h01 HE
|
Lumos Pharma, Inc.
-- Continue to Anticipate Interim Data from Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials in Q4 2022 -- -- Primary Outcome Readouts from Both Trials Anticipated 2H 2023 with Data in up to 24...
Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022
27 juil. 2022 16h05 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will report its second quarter 2022 financial...
Lumos Pharma to Participate in Upcoming Investor Conferences
16 mai 2022 16h05 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company...